Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

PredictAYA Prediction and prevention of late effects in AYA cancer survivors – An effort to understand, predict and prevent late effects in AYAs 15-39 years of age, with a focus on fertility and gonadal toxicity

Coordinator
Karolinska Institutet, Sweden
Runs
1 June 2025 to 31 May 2030
Status
Running
EU funding
€6.3m
Total cost
€6.3m
Partners
19 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101214879

What the project is doing

In the project's own words, from its summary on CORDIS.

PredictAYA is a multidisciplinary effort to fully address and improve the understanding of late effects in AYAs 15-39 years treated for cancer, by building on data from existing populations-based registers, large genomic biobanks and newly established clinical AYA cohorts. Importantly, the patient perspective will be captured in our clinical cohorts and patients’ care preferences and needs including the psychosocial impact of cancer treatment on reproductive health, sexuality and quality of life in AYAs.

By cooperation between clinicians, researchers, psychologists, oncology nurses and with patient involvement, the study will use a participatory research approach and develop in co-creation with representative AYAs with cancer. This action is part of the Cancer Mission cluster of projects on “Quality of life (AYA). Our long-term goal is to develop a panel of validated biomarkers to identify individuals at high-risk of organ toxicities, aiming at clinical implementation and future individualized screening and counselling.

Our main focus is on reproductive toxicity and through innovative precision medicine and pharmacogenetics, we will identify genetic biomarkers explanatory for interindividual variation in treatment induced toxicity among AYAs. A model on constitutional genetic risk for reproductive organ toxicity will be evaluated in clinical cohorts across Europe. Future precision-medicine applications and clinical implementation are envisaged as potential benefit of our proposal.

Additional research questions include the prevalence, severity and timing of gonadal toxicity for different cancer treatments in both sexes, the timing and risks of pregnancy, the risk of accelerated aging, the health of the children born to AYAs. The safety and efficacy of fertility preservation methods will be investigated in detail. Our methodology will also allow us to investigate additional phenotypes and find associations among reproductive, endocrine, cardiac and neurologic toxicity, risk factors including social and health determinants and comorbidity patterns.

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator
Medizinische Universitat InnsbruckInnsbruckAustriaParticipant
European Cancer OrganisationBruxelles / BrusselBelgiumParticipant
Universite Libre De BruxellesBruxellesBelgiumParticipant
Universitaet BernBernSwitzerlandAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Universitaet LeipzigLeipzigGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
Mtu Civitta FoundationTartuEstoniaParticipant
Tartu UlikoolTartuEstoniaParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Fondazione Irccs Istituto Nazionale Dei TumoriMilanItalyParticipant
Irccs Azienda Ospedaliera MetropolitanaGenovaItalyParticipant
Universita Degli Studi Di FirenzeFlorenceItalyParticipant
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Linkopings UniversitetLinkopingSwedenParticipant
Region StockholmStockholmSwedenParticipant
The University of EdinburghEdinburghUnited KingdomParticipant
University of LeedsLeedsUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI